Vertex Pharmaceuticals (VRTX) Income towards Parent Company (2009 - 2026)

Vertex Pharmaceuticals' Income towards Parent Company history runs 17 years deep, the most recent figure standing at $1.0 billion for Q1 2026.

• On a quarterly basis, Income towards Parent Company rose 59.59% year-over-year to $1.0 billion in Q1 2026; TTM through Mar 2026 was $4.3 billion, a 538.7% increase from a year earlier, with the FY2025 full-year figure at $4.0 billion, up 838.09% from the prior year.
• Income towards Parent Company eased to $1.0 billion in Q1 2026 per VRTX's latest filing, from $1.2 billion in the prior quarter.
• Across five years, Income towards Parent Company topped out at $1.2 billion in Q4 2025 and bottomed at -$3.6 billion in Q2 2024.
• The 5-year median for Income towards Parent Company is $930.5 million (2022), against an average of $670.0 million.
• Across the five-year window, Income towards Parent Company soared 1109.7% in 2022 and tumbled 492.44% in 2024, its largest moves.
• Year by year, Income towards Parent Company stood at $818.9 million in 2022, then grew by 18.31% to $968.8 million in 2023, then decreased by 5.76% to $913.0 million in 2024, then jumped by 30.46% to $1.2 billion in 2025, then decreased by 13.41% to $1.0 billion in 2026.
• Per Business Quant, the three latest VRTX Income towards Parent Company figures stand at $1.0 billion (Q1 2026), $1.2 billion (Q4 2025), and $1.1 billion (Q3 2025).